Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.61 |
| ▸ | INSR | P06213 | 6/20 | 0.57 |
| ▸ | LYN | P07948 | 5/20 | 0.57 |
| ▸ | LCK | P06239 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.57 |
| ▸ | FLT4 | P35916 | 4/20 | 0.57 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.57 |
| ▸ | CSF1R | P07333 | 3/20 | 0.57 |
| ▸ | MARK3 | P27448 | 3/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.57 |
| ▸ | BLK | P51451 | 3/20 | 0.57 |
| ▸ | NEK2 | P51955 | 3/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.57 |
| ▸ | STK3 | Q13188 | 3/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.57 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.57 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096003 | 0.78 | IGF1R (0.69) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL11345478 | 0.76 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL6215806 | 0.76 | IGF1R (0.75) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL3685466 | 0.76 | IGF1R (0.75) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL11345526 | 0.76 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL14050381 | 0.76 | IGF1R (0.72) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL6215783 | 0.75 | IGF1R (0.85) | IGF1RINSRLYNLCKKDR | |
| Dimethylcarbate SCHEMBL6217753 | 0.75 | IGF1R (0.85) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL4825191 | 0.75 | IGF1R (0.76) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL4825232 | 0.75 | IGF1R (0.76) | IGF1RINSRLYNLCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | IGF1R 3898/4885INSR 2996/4885LYN 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.